Wolfe Research Upgrades Kymera Therapeutics to Outperform, Announces $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wolfe Research has upgraded Kymera Therapeutics to 'Outperform' with a new price target of $65, indicating a positive outlook for the company's stock.
August 26, 2024 | 10:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wolfe Research has upgraded Kymera Therapeutics to 'Outperform' and set a price target of $65, suggesting a positive short-term outlook for the stock.
The upgrade from 'Peer Perform' to 'Outperform' by Wolfe Research, along with a specific price target of $65, indicates a strong positive sentiment from analysts. This is likely to boost investor confidence and could lead to an increase in KYMR's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100